Cinclus Pharma Expects HEEALING1 Top-Line Results Following Patient Randomization
Cinclus Pharma Holding AB (CPHHF) has announced that top-line results for its lead asset, linaprazan glurate, are expected later this quarter. The clinical milestone follows the successful randomization of 523 patients in the HEEALING1 study. The drug is being developed to treat severe erosive gastroesophageal reflux disease (GERD). CEO Christer Ahlberg highlighted a significant commercial opportunity, noting that the target patient population includes approximately 10 million people across the U.S. and Europe, with a global reach of roughly 19 million individuals.
Topics: drug development earnings call GERD market opportunity